Starpharma Holdings Ltd
PQ6A
Company Profile
Business description
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
Contact
4-6 Southampton Crescent
Abbotsford
MelbourneVIC3067
AUST: +61 385322700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
32
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,263.74 | 25.57 | 0.31% |
| DAX 40 | 24,617.38 | 126.32 | 0.52% |
| Dow JONES (US) | 49,683.57 | 182.27 | 0.37% |
| FTSE 100 | 10,351.26 | 42.04 | 0.41% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 22,679.05 | 225.53 | -0.98% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,861.29 | 62.89 | 0.93% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |